JLPC announced that its wholly-owned subsidiary, JLPC Co., Ltd., intends to purchase certain buildings and land use rights from its controlling shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd.'s controlling subsidiary, Prinx Pharmaceutical Technology Co., Ltd., for a transaction price of 74.5 million RMB. This transaction constitutes a related party transaction and does not constitute a major asset reorganization as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies." The transaction has been approved by the company's board of directors and supervisory board and is subject to approval by the company's shareholders' meeting, as well as the completion of state-owned asset approval and transfer registration procedures. This transaction aims to optimize resource allocation, expand asset scale, and enhance overall strength
